Correlation Between Vaxcyte and Structure Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Vaxcyte and Structure Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Vaxcyte and Structure Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Vaxcyte and Structure Therapeutics American, you can compare the effects of market volatilities on Vaxcyte and Structure Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Vaxcyte with a short position of Structure Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Vaxcyte and Structure Therapeutics.

Diversification Opportunities for Vaxcyte and Structure Therapeutics

0.1
  Correlation Coefficient

Average diversification

The 3 months correlation between Vaxcyte and Structure is 0.1. Overlapping area represents the amount of risk that can be diversified away by holding Vaxcyte and Structure Therapeutics America in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Structure Therapeutics and Vaxcyte is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Vaxcyte are associated (or correlated) with Structure Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Structure Therapeutics has no effect on the direction of Vaxcyte i.e., Vaxcyte and Structure Therapeutics go up and down completely randomly.

Pair Corralation between Vaxcyte and Structure Therapeutics

Given the investment horizon of 90 days Vaxcyte is expected to generate 0.9 times more return on investment than Structure Therapeutics. However, Vaxcyte is 1.11 times less risky than Structure Therapeutics. It trades about 0.02 of its potential returns per unit of risk. Structure Therapeutics American is currently generating about -0.08 per unit of risk. If you would invest  3,173  in Vaxcyte on May 27, 2025 and sell it today you would earn a total of  56.00  from holding Vaxcyte or generate 1.76% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Vaxcyte  vs.  Structure Therapeutics America

 Performance 
       Timeline  
Vaxcyte 

Risk-Adjusted Performance

Weak

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Vaxcyte are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong basic indicators, Vaxcyte is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors.
Structure Therapeutics 

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Structure Therapeutics American has generated negative risk-adjusted returns adding no value to investors with long positions. Even with unfluctuating performance in the last few months, the Stock's fundamental indicators remain relatively invariable which may send shares a bit higher in September 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Vaxcyte and Structure Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Vaxcyte and Structure Therapeutics

The main advantage of trading using opposite Vaxcyte and Structure Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Vaxcyte position performs unexpectedly, Structure Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Structure Therapeutics will offset losses from the drop in Structure Therapeutics' long position.
The idea behind Vaxcyte and Structure Therapeutics American pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Other Complementary Tools

Content Syndication
Quickly integrate customizable finance content to your own investment portal
Global Correlations
Find global opportunities by holding instruments from different markets
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency